RAC1 and melanoma: The deficiency of RAC1 can amplify the inhibitory effect of BRAF-targeted agent on melanoma cell survival.417 In addition, low MITF/AXL ratio that indicates the phenotypic plasticity of melanoma cells is reported to determine the intrinsic response to targeted therapy.